Datasetspublic full text
ClinicalTrials.gov
clinicaltrials · Datasets · License: Public Domain
178,442Documents
1,450Full text
2026-09-30Last indexed
Recent documents from this source
- Magnetic Resonance Imaging of Patients With Normal Tension Glaucoma#180227
- A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine#180226
- A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults#180225
- Chikungunya Virus Vaccine Trial in Healthy Adults#180224
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age#180223
- Treatment and Vaccine Development of Mycoplasma Pneumoniae#180222
- Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE#180221
- Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients#180220
- Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients#180219
- Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)#180218
- Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)#180217
- Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence#180216
- Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults#180215
- Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors#180214
- Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination#180213
- Text Message Nudges for COVID-19 Vaccination#180212
- The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.#180211
- A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older#180210
- Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.#180209
- Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection#180208
Source record · clinicaltrials · Datasets · License: Public Domain
Conceptio Open Knowledge Archive — counts are materialised per sync from the index (real full-text coverage, never license entitlement).